3.4.22 | Maternal Health
SWHR CEO Reflects on Reproductive Health Innovation Summit
SWHR CEO Kathryn G. Schubert spoke at the 2022 Reproductive Health Innovation Summit, in February 2022. Here, she reflects on the event and shares how we can help to advance women’s health.
2.8.22 | Research and Clinical Trials
Dr. Jill Becker Builds a Vision for the Future of Biology of Sex Differences
Dr. Jill Becker, editor-in-chief at Biology of Sex Differences (BSD), shared her journey through science research and her work to drive women’s health research forward.
11.8.21 | Health Equity
Disparities in Biomedical Research: A Women’s Health Issue
This blog summarizes the state of disparities in biomedical research and how they might be addressed.
9.15.21 | Policy
SWHR Submits Comments to Inform ORWH Women’s Health Consensus Conference
SWHR this week submitted comments in response to the National Institutes of Health (NIH) Office of Research on Women's Health (ORWH) Request for Information: Inviting Comments to Inform the Women's Health Consensus Conference (WHCC).
5.18.21 | Coronavirus
COVID-19 Vaccines: Sex Differences in Immune Responses
Disaggregating clinical trial data by sex and gender could ultimately help us understand and respond to disparities in vaccination more quickly.
5.12.21 | Policy
SWHR Launches Coalition to Support NIH Office of Research on Women’s Health
During National Women's Health Week, SWHR launched a new coalition to support the important work of the NIH Office of Research on Women’s Health.
4.7.21 | Research and Clinical Trials
Panel: Improving Diversity in Clinical Trials Better Serves Patients
Researchers and health care stakeholders must actively pursue more representative clinical trials and make changes that encourage the participation of historically marginalized groups within the research community.
3.9.21 | Research and Clinical Trials
People of Color Continue to Be Underrepresented in Research on New Drugs
After decades of being underrepresented in biomedical research, women have accounted for more than 50% of participants in clinical trials for FDA-approved new drugs in the past four years.
